Physician profile
Vasanth Sathiyakumar
NPI 1154716082
$19,974.91
in general payments reported to CMS, 2019-2025
29 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $795 · 2023: $1,784 · 2024: $2,072 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,728 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,600 · Food and Beverage: $4,556 · Travel and Lodging: $19.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,727.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,600.00 |
| Food and Beverage | $4,555.69 |
| Travel and Lodging | $19.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14,030.25 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $2,405.13 | 2021-2025 | |
| Novo Nordisk INC | $619.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $436.60 | 2021-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $409.58 | 2022-2025 | Verquvo, Capvaxive |
| Heartflow, INC. | $228.36 | 2023 | Ffrct |
| Boston Scientific Corporation | $223.56 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $211.63 | 2021-2025 | Lifevest |
| Pfizer INC. | $203.60 | 2023-2024 | |
| Amarin Pharma, INC. | $161.86 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $135.10 | 2023-2025 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals Lp | $117.53 | 2021-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $84.96 | 2022-2023 | Xarelto |
| Philips North America LLC | $77.31 | 2023-2025 | Extended Holter |
| Kiniksa Pharmaceuticals International, Plc | $70.51 | 2024 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $63.33 | 2023 | Inspire |
| Impulse Dynamics (USA) INC. | $61.62 | 2023 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.23 | 2022-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $51.78 | 2022-2025 | |
| Medtronic, INC. | $45.92 | 2025 | Corevalve Evolut R |
| Itamar Medical INC | $45.79 | 2022-2025 | Watchpatone |
| Abiomed | $43.64 | 2024 | Impella |
| Bridgebio Pharma, INC. | $40.65 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $39.12 | 2025 | Evkeeza |
| Esperion Therapeutics, INC. | $37.00 | 2023 | Nexletol |
| Cvrx, INC. | $19.48 | 2024 | Barostim Neo System |
| Cardiva Medical, INC. | $19.10 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.14 | 2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $16.59 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasanth Sathiyakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.